Stocks Health care HALO
NASDAQ · Health careHalozyme Therapeutics, Inc. (HALO)
Halozyme Therapeutics, Inc. brought in $1.7B of revenue over the twelve months to June 30, 2026, up 41.2% from a year earlier. Net income was $413.6M, a net margin of 24.9%. Operating cash flow minus capital spending left $644.6M of free cash flow in fiscal 2025. At June 30, 2026 it held $163.1M in cash against $2.1B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Halozyme Therapeutics, Inc. does
Halozyme Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker HALO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.4B | $316.9M | $2.56 | $644.6M |
| 2024 | $1B | $444.1M | $3.43 | $468.4M |
| 2023 | $829.3M | $281.6M | $2.10 | $373.3M |
| 2022 | $660.1M | $202.1M | $1.44 | $235.3M |
| 2021 | $443.3M | $402.7M | $2.74 | $298M |
| 2020 | $267.6M | $129.1M | $0.91 | $53M |
Latest SEC filings
What Halozyme Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 22, 2026
- September 18, 2026Other event 8-K
- September 16, 2026Other event 8-K
- August 18, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- July 2, 2026
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026
- May 11, 2026
- May 7, 2026
Questions about HALO
What does Halozyme Therapeutics, Inc. do?
Halozyme Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker HALO.
Is Halozyme Therapeutics, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $413.6M on revenue of $1.7B, a net margin of 24.9%.
How much revenue does Halozyme Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Halozyme Therapeutics, Inc. reported revenue of $1.7B. That is 41.2% more than a year earlier.
When did Halozyme Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 22, 2026.
Similar companies
Follow HALO
Get an email when Halozyme Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow HALO: get an email when it filesWhere the numbers come from
Financial figures are the values Halozyme Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.